Showing results (171-180 of 192) with videos related to
Sort By:
Pageof 20
Revue Medicale De Bruxelles|November 24, 2015
[Practical approach of lymphomas: major role of general practitioner who has to face all these emerging drugs]D Bron, R Dewind, B Cantinieaux, et al.Nature|April 1, 2005
Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritisSonya S Glasson, Roger Askew, Barbara Sheppard, et al.The New England Journal of Medicine|December 7, 1995
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphomaT Philip, C Guglielmi, A Hagenbeek, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
EORTC study of non-Hodgkin's lymphoma: phase III study comparing CHVmP-VB and ProMACE-MOPP in patients with stage II, III, and IV intermediate- and high-grade lymphomaR Somers, P Carde, J Thomas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study GroupU Tirelli, D Errante, M Van Glabbeke, et al.Osteoarthritis and Cartilage|December 18, 2010
Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitorP S Chockalingam, W Sun, M A Rivera-Bermudez, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative GroupJ H Meerwaldt, P Carde, R Somers, et al.Haematologica|July 16, 1999
The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factorM F Dresse, M Boogaerts, C Vermylen, et al.Arthritis and Rheumatism|August 31, 2004
Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout miceSonya S Glasson, Roger Askew, Barbara Sheppard, et al.Journal of the National Cancer Institute|January 4, 2001
Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC studyH C Kluin-Nelemans, V Zagonel, A Anastasopoulou, et al.Pageof 20